Diabetes drug and conflicts of interest
By Janet Raloff, 15:58 PM April 15, 2008
So much for confidential peer review.
Last May, a controversial paper in the New England Journal of Medicine (NEJM) reported that a popular diabetes drug—rosiglitazone, sold as Avandia—substantially hikes a user's risk of heart attack (SN: 6/23/07, p. 397). But according to an ongoing investigation by the U.S. Senate Committee on Finance, Avandia's maker knew about the study before it was published. The company—Philadelphia-based GlaxoSmithKline—had a leaked copy, courtesy of a scientist that...
Source URL: https://www.sciencenews.org/article/diabetes-drug-and-conflicts-interest